GNFT scalable MASH diagnostics projections point to $1.5B+ U.S. sales by 2033
A hepatology expert said there is urgent need for scalable, non-invasive MASH diagnostics. Projections cited U.S. peak sales that could exceed $1.5 billion by 2033, helped by new therapies and adoption.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.